GlassScriptPhysician profile
Joanna Pruzon
NPI 1649201112
$5,095.09
in general payments reported to CMS, 2019-2025
25 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $242 · 2021: $1,099 · 2022: $755 · 2023: $743 · 2024: $839 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,705.25 | 2019-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $521.80 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $511.37 | 2022-2025 | Vyzulta, Prolensa, Miebo |
| Tarsus Pharmaceuticals, INC. | $427.43 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $348.24 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Dompe US, INC. | $275.65 | 2019-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $222.29 | 2019-2022 | |
| Ocular Therapeutix, INC. | $153.21 | 2021-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $119.58 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.87 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $88.76 | 2019-2023 | Tobradex St |
| Abbvie INC. | $87.69 | 2022-2024 | |
| Alcon Vision LLC | $81.30 | 2020-2025 | Clareon, Clareon Panoptix Pro |
| Kala Pharmaceuticals, INC. | $74.40 | 2021-2022 | |
| Biotissue Holdings INC. | $64.84 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $56.36 | 2024 | Ilevro |
| Novartis Pharmaceuticals Corporation | $53.50 | 2020-2021 | |
| Oyster Point Pharma, INC. | $41.72 | 2022-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $39.61 | 2025 | Acthar |
| Mallinckrodt Enterprises LLC | $26.01 | 2019 | |
| Aerie Pharmaceuticals, INC. | $24.14 | 2021 | |
| Thea Pharma INC. | $21.24 | 2024 | Iyuzeh |
| New World Medical,INC. | $17.69 | 2025 | Ahmed Glaucoma Valve, Via360, Clearpath |
| Glaxosmithkline, LLC. | $15.08 | 2023 | Nucala |
| Eyepoint US, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Pruzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.